Compare Bristol-Myers Squibb Co (BMY) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Core MSCI Emerging Markets ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.56 (market cap $116.30B), while iShares Core MSCI Emerging Markets ETF trades at $79.47. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals.
| BMY | IEMG | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $86.00 |
52-Week Low | $42.60 | $59.90 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
IEMG is trading at $78.49, down 3.49% over the past 24 hours amid a bearish technical signal. The ETF has delivered strong performance with a 35% surge over the past year, driven by its 40% technology weighting and exposure to South Korean and Taiwanese semiconductor stocks. Recent news highlights record inflows into emerging markets and IEMG's cost advantage over competitors like EEM with its 0.09% expense ratio.
The outlook for IEMG remains mixed with attractive emerging market valuations and AI-driven growth potential balanced against elevated volatility and geopolitical risks. While the fund offers diversified exposure to fast-growing economies, investors face concentration risks in tech stocks and potential headwinds from US-China trade tensions that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
